[Ad hoc-Mitteilung gemäss Art. 53 KR] Roche verzeichnet starkes Wachstum im Basisgeschäft beider Divisionen; Konzernverkäufe und -gewinn widerspiegeln rückläufige Nachfrage nach COVID-19-Produkten
July 27, 2023 01:00 ET
|
F. Hoffmann-La Roche Ltd
Basel, 27. Juli 2023 Verkäufe der Roche-Gruppe ohne COVID-19-Produkte steigen deutlich um 8%1 zu konstanten Wechselkursen (CER) Durch die erwartungsgemäss rückläufige Nachfrage nach...
[Annonce événementielle au sens de l’art. 53 RC] Roche fait état d’une forte croissance de son activité de base dans ses deux divisions ; les ventes et le bénéfice du groupe reflètent la baisse des ventes de produits liés au COVID-19
July 27, 2023 01:00 ET
|
F. Hoffmann-La Roche Ltd
Bâle, le 27 juillet 2023 Sans les produits liés au COVID-19, le chiffre d’affaires consolidé a fortement augmenté de 8 %1 à taux de change constants (TCC) Conformément à la baisse de la demande...
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong growth in both divisions’ base business; Group sales and profit reflect declining demand for COVID-19 products
July 27, 2023 01:00 ET
|
F. Hoffmann-La Roche Ltd
Basel, 27 July 2023 Excluding COVID-19 products, Group sales increase strongly by 8%1 at constant exchange rates (CER) In line with the expected declining demand for COVID-19 products, Group sales...
Roche enters partnership with Alnylam to co-develop and co-commercialise RNAi therapeutic zilebesiran to treat hypertension in patients with high cardiovascular risk
July 24, 2023 01:00 ET
|
F. Hoffmann-La Roche Ltd
Partnership combines Roche’s proven track record of successfully developing and launching innovative medicines worldwide with Alnylam’s leadership in RNAi therapeuticsZilebesiran, a Phase 2 RNAi...
CHMP recommends Roche’s Evrysdi for babies under two months old with spinal muscular atrophy (SMA)
July 21, 2023 09:30 ET
|
F. Hoffmann-La Roche Ltd
Positive recommendation is based on interim data from ongoing RAINBOWFISH trial which showed majority of Evrysdi-treated babies were able to stand and walk within timeframes typical of healthy babies...
New clinical and real-world data for Roche’s Vabysmo at ASRS reveal improved outcomes for people with two leading causes of vision loss
July 20, 2023 01:00 ET
|
F. Hoffmann-La Roche Ltd
Late-breaking post-hoc data indicate Vabysmo leads to less fibrosis, which may negatively impact vision, than aflibercept in people with diabetic macular edema (DME)Real-world data reinforce that...
Positive Phase III results for Roche’s OCREVUS (ocrelizumab) twice a year, 10-minute subcutaneous injection in patients with multiple sclerosis
July 13, 2023 01:00 ET
|
F. Hoffmann-La Roche Ltd
Phase III OCARINA II trial met primary and secondary endpoints OCREVUS twice a year, 10-minute injection has the potential to further improve the treatment experience and expand OCREVUS usage in MS...
European Commission approves Roche’s fixed-duration Columvi (glofitamab) for people with relapsed or refractory diffuse large B-cell lymphoma
July 11, 2023 01:00 ET
|
F. Hoffmann-La Roche Ltd
Columvi is the first CD20xCD3 T-cell-engaging bispecific antibody available in Europe to treat the most common and aggressive form of lymphoma Approval is based on results from the phase I/II...
Four-year follow up data for Roche’s Evrysdi show continued increase in number of children with a severe form of spinal muscular atrophy (SMA) able to sit, stand and walk
June 30, 2023 11:50 ET
|
F. Hoffmann-La Roche Ltd
Data from ongoing FIREFISH study confirm long-term efficacy and safety profile of Evrysdi in children with Type 1 SMANinety-one percent of children were alive at month 48More than 95% maintained the...
FDA approves Roche’s Columvi, the first and only bispecific antibody with a fixed-duration treatment for people with relapsed or refractory diffuse large B-cell lymphoma
June 16, 2023 01:00 ET
|
F. Hoffmann-La Roche Ltd
Pivotal study showed durable responses, with a 56% overall response rate, a 43% complete response (remission) rate and a median duration of response of 1.5 years (18.4 months)1Given over a fixed...